Compare Coinbase Global, Inc. (COIN) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coinbase Global, Inc. vs Mesoblast Limited — how do they compare? Coinbase Global, Inc. trades at $180 (market cap $45.38B), while Mesoblast Limited trades at $14.24 (market cap $1.75B). The key difference: Coinbase Global, Inc. is far larger — about 25.9× Mesoblast Limited's market cap, and Mesoblast Limited is more actively traded (239,027 versus 11,013,940). Which is the better fit depends on your goals — on Pluang, investors hold Coinbase Global, Inc. for 78 Days and Mesoblast Limited for 15 Days on average.
| COIN | MESO | |
|---|---|---|
Market Cap | $45.38B | $1.75B |
Volume | 11,013,940 | 239,027 |
Sector | Financials | Health |
52-Week High | $387.00 | $20.96 |
52-Week Low | $141.09 | $13.19 |
Typical Hold Time | 78 Days | 15 Days |
Enterprise Value | $43.03B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COIN trades at $179.39, up 0.53% today, with a bullish technical signal despite recent earnings misses. Revenue grew to $7.18B in 2025, but net income margin turned negative at -15.72%. The company maintains strong cash flow from operations at $2.43B and holds $9.55B in cash. Recent CFTC approval for derivatives clearing and expanded Citigroup partnership signal strategic expansion.
Outlook remains mixed with 55% analyst buy ratings and a $211.91 price target, but negative profitability and projected 2026 net loss of -$988M pose significant risks. Stock performance hinges on execution in derivatives and stablecoin initiatives amid volatile crypto markets.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
